Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients

Renal Failure

Volumn 32, Issue 9, 2010, Pages 1109-1114

  Hakeshzadeh, Fariba ^a   Tabibi, Hadi ^a   Ahmadinejad, Minoo ^b   Malakoutian, Tahereh ^c   Hedayati, Mehdi ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

anticoagulation factors; coagulation factors; hemodialysis; inflammation; L carnitine

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8C; C REACTIVE PROTEIN; CARNITINE; FIBRINOGEN; HEPARIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AGED; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CARNITINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; THROMBOPHILIA; VITAMIN B COMPLEX;

EID: 77957278786     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.510617     Document Type: Article

References (27)

1. Jungers P, Khoa TN, Massy ZA, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patient: A multicentric study in the Ile De France district. Nephrol Dial Transplant. 1999;14:898-902. (Pubitemid 29155144)
2. Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrol Dial Transplant. 2002;17(Suppl. 8):33-38. (Pubitemid 34918877)
3. Ambuhl PM, Wuthrich RP, Korte W, Schmid L, Krapf R. Plasma hypercoagulability in hemodialysis patients: Impact of dialysis and anticoagulation. Nephrol Dial Transplant. 1997;12:2355-2364. (Pubitemid 27474619)
4. Smits JHM, Liden J, Blankestijn PJ, Rabelink TJ. Coagulation and hemodialysis access thrombosis. Nephrol Dial Transplant. 2002;15:1755-1760.
5. Song IS, Yang WS, Kim SB, Lee JH, Kwon TW, Park JS. Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients. Nephrol Dial Transplant. 1999;14:1137-1141.
6. Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis. 1994;23:828-835. (Pubitemid 24173566)
7. Oda H, Ohno M, Ohashi H. Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease. Adv Perit Dial. 2000;16:152-155.
8. Segarra A, Chacon P, Martinez-Eyarre C, et al. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol. 2001;12:1255-1263. (Pubitemid 32472640)
9. Lottermoser K, Petras S, Poge U, et al. The fibrinolytic system in chronic renal failure. Eur J Med Res. 2001;6:372-376.
10. Molino D, De Santo NG, Marotta R, Anastasio P, Mosavat M, De Lucia D. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol. 2004;24:495-501. (Pubitemid 39361062)
11. Trimarchi H, Duboscq C, Genoud V, et al. Plasminogen activator inhibitor-1 activity and 4G/5G polymorphism in hemodialysis. J Vasc Access. 2008;9:142-147.
12. Deguchi K, Izumi K, Noguchi M, et al. Coagulation and fibrinolysis in patients with chronic renal failure on maintenance hemodialysis (abstr). Nippon Ketsueki Gakkai Zasshi. 1989;52:140-146.
13. Vaziri ND, Toohey J, Paule P, Alikhani S, Hung E. Coagulation abnormalities in patients with end-stage renal disease treated with hemodialysis. Int J Artif Organs. 1984;7:323-326. (Pubitemid 15159103)
14. Uchida Y. Long-term hemodialysis and changes in variables of coagulation and fibrinolysis (abstr). Fukuoka Igaku Zasshi. 1991;82:576-585.
15. Erdem Y, Haznedaroglu IC, Celik L, et al. Coagulation, fibrinolysis and fibrinolysis inhibitors in hemodialysis patients: Contribution of arteriovenous fistula. Nephrol Dial Transplant. 1996;11:1299-1305. (Pubitemid 26241419)
16. Pola P, De Martini D, Gerardino L, De Rossi S, Tondi P. The action of propionyl-L-carnitine on the vasal endothelium: Increased t-PA synthesis and a decrease in the activity of PAI- 1. A preliminary study. Drugs Exp Clin Res. 1992; 18:343-348. (Pubitemid 23064010)
17. Daugirdas JT, Stone JCV. Physiologic principles and urea kinetic modeling. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 3rd ed., Philadelphia: Lippincott Williams & Wilkins; 2001:15-45.
18. Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis. 2003;41(Suppl. 4):S13-S26. (Pubitemid 36389776)
19. Alberty R, Albertyova D. Biological variation of free and total carnitine in serum of healthy subjects. Clin Chem. 1997;43:2441-2443.
20. Guarnieri G, Biolo G, Vinci P, Massolino B, Barazzoni R. Advances in carnitine in chronic uremia. J Ren Nutr. 2007;17:23-29. (Pubitemid 46014452)
21. Elisaf M, Bairaktari E, Katopodis K, et al. Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients. Am J Nephrol. 1998;18:416-421. (Pubitemid 28442105)
22. Guarnieri GF, Ranieri F, Toigo G, et al. Lipid lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am J Clin Nutr. 1980;33:1489-1492. (Pubitemid 10013693)
23. Libby P, Simon DI. Inflammation and thrombosis. Circulation. 2001;103:1718-1720.
24. Savica V, Santoro D, Mazzaglia G, et al. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr. 2005;15:225-230. (Pubitemid 40502092)
25. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yücel D. Effects of L-carnitine infusions on inflammatory and nutritional markers in hemodialysis patients. Nephrol Dial Transplant. 2006;21:3211-3214. (Pubitemid 44567096)
26. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. J Am Med Assoc. 2005;294:1799-1809. (Pubitemid 41434626)
27. Undas A, Kolarz M, Kopec G, Tracz W. Altered fibrin clot properties in patients on long-term hemodialysis: Relation to cardiovascular mortality. Nephrol Dial Transplant. 2008;23: 2010-2015. (Pubitemid 351768150)